New Combination Therapy Safe, Promising For Melanoma Patients
Sunday, June 1, 2008 - 16:35
in Health & Medicine
Researchers in the melanoma and skin cancer program at the University of Pittsburgh Cancer Institute combined two biotherapies, high-dose interferon alfa-2b and tremelimumab, and found the combination may be beneficial for patients with inoperable melanoma. The study has since moved into the second stage, where it will enroll 21 additional patients.